ClinicalTrials.gg
RecruitingNCT06724653HFrecEFUpdated Mar 27, 2026

Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial

An interventional study of RAS blocker tapering group and Beta blocker tapering out in Heart Failure, Ejection Fraction and Recovery of Function, sponsored by Chungnam National University Hospital. Recruiting at 2 sites in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Chungnam National University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 148 studies in Heart Failure with a site in Korea, Republic of — 48 open to participants now, 54 under way, 12 of them phase 3. Heart Failure · Korea, Republic of.

Planned enrollment
66th of 109
150 · median 227
Started
2025
with 14 others
No phase
33 of 148
13 open now
Primary completion
2025-05
later than 3 of 53 live
Registered
112th of 148
by date

Among the 148 studies in Heart Failure with a site in Korea, Republic of, this one is the 66th largest by planned enrollment of the 109 interventional ones that give a count, is one of 15 that started in 2025, is one of 33 with no phase, reaches primary completion later than 3 of the 53 other live ones, and was the 112th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

48 of the 148 studies in Heart Failure with a site in Korea, Republic of are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 148 studies in Heart Failure with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Study start date is on Nov 27th 2024.

A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.

Read the detailed description

Patients described above randomly assigned to drug tapering group and drug maintaining group.

Drug tapering group is 2 groups, which one is RAS blocker tapering group and others is beta blocker tapering group.

Drug tapering group is monitored ejection fraction, LV dimension and LV GLS by 1-3 month.

03

Conditions studied

  • Heart Failure
  • Ejection Fraction
  • Recovery of Function

Browse trials for

Keywords

  • heart failure with recovered ejection fraction
  • Tapering
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • initial echocardiogram less than 40%
  • follow up echocardiogram ejection fraction over 50% and LVEDD index normal range
  • NTprobnp criteria

    1. ≥60 ; less 440
    2. eGFR 45-59: less 980
    3. eGFR 30-44; less 1220
    4. eGFR \< 30 : less 5300
    5. in HD; no criteria for NTproBNP
  • on more than 3 heart failure medication ( RAS blocker, beta blocker, mineral corticoid receptor antagonist, SGLT 2 inhibitor)

Exclusion criteria

Exclusion Criteria:

  1. under age 18 year
  2. uncontrolled BP ( over 150/90)
  3. coronary revascularization within 6 months
  4. significant valve disease
  5. arrhythmia requiring rate control
  6. CKD with albuminuria ( over 30mg/g)
  7. Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    RAS blocker tapering arm

    RAS blocker tapering

    Drug: RAS blocker tapering group · Drug: Beta blocker tapering out

  • Active comparator
    Beta blocker tapering arm

    Beta blocker tapering arm

  • Placebo comparator
    Control

    Drug maintain group

Interventions

  • DrugRAS blocker tapering group

    RAS blocker tapering out

  • DrugBeta blocker tapering out

    Beta blocker tapering out group

06

What researchers measure

Primary outcomes

  1. Heart failure relapse

    LVEF 10% drop, EF less than 50 %, LVIDd/BSA 10% increase, over 33mm/m\^2

    Time frame: From enrollment to the end of treatment at 18 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Beginning 3 months after the publication of results with no end date

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in May 2025, 2 months.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's 2 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2024
First posted
Dec 9, 2024
StartActual
Mar 6, 2025
Primary completionActual
May 26, 2025
CompletionEst.
Nov 26, 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06724653
Lead sponsor
Chungnam National University Hospital
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Mar 6, 2025
Primary completion
May 26, 2025
Completion
Nov 26, 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

Yujin Yang
Contact
wjsdudtns9@gmail.com
821043311245

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion